Children's Hospital Boston and Proteus to Introduce New Algae-Derived Anesthetic

Children's Hospital Boston has signed an agreement to work with biotech start-up Proteus on the clinical adoption of a new anesthetic derived from algae, according to a BioScholar report.

In a double-blind, randomized trial, patients experienced significantly less postoperative pain and recovered approximately two days sooner when they received the new anesthetic, neosaxitoxin. Neosaxitoxin is a site 1 sodium-channel blocker based on molecules derived from aquatic organisms. Unlike other local anesthetics, which usually last for less than eight hours, neosaxitoxin provides local anesthesia for more than 24 hours.

The study was reported in the March-April issue of Regional Anesthesia and Pain Medicine.

Read the BioScholar report on neosaxitoxin.

Read more on anesthesia:

-Abbott Northwestern Hospital Nurse Arrested for Stealing Patient Anesthetic

-Melatonin Can Relieve Surgical Pain in Children Says UC Irvine Anesthesiologist

-Case Study: Artery May Interfere With Cervial Radiofrequency Neurotomy

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast